Literature DB >> 1704822

In vivo formation and repair of O6-methylguanine in human leukocyte DNA after intravenous exposure to dacarbazine.

V L Souliotis1, V A Boussiotis, G A Pangalis, S A Kyrtopoulos.   

Abstract

Blood leukocyte DNA obtained from 11 Hodgkin's disease patients undergoing ABVD chemotherapy was analysed for the presence of the precarcinogenic adduct O6-methylguanine (O6-meG) at various times (1-2 h up to 49 h) after i.v. treatment with the methylating drug dacarbazine. Adduct formation was detected in all but one of the patients examined at levels ranging up to 0.45 fmol/micrograms DNA (7.2 x 10(-7) mol/mol guanine). The levels of the adduct decreased by approximately 30% over the 24 h following exposure and were usually not detectable 49 h after exposure. In five out of seven individuals examined after more than one treatment, consistent methylation responses were noted, while in the remaining two cases the responses were mixed. No correlation between the extent of adduct formation and lymphocyte levels of the repair enzyme O6-alkylguanine-DNA alkyltransferase was observed. The average extent of O6-meG formation 1 h after dacarbazine treatment was (4.3 +/- 3.1) x 10(-2) fmol/micrograms DNA per mg/kg dose [( 1.2 +/- 0.8) x 10(-3) fmol/micrograms DNA per mg/m2 dose)]. Following exposure of rats to similar doses of dacarbazine, the corresponding levels of adduct in blood leukocyte DNA were 1.1 x 10(-2) fmol/micrograms DNA per mg/kg dose (2.6 x 10(-3) fmol/micrograms DNA per mg/m2 dose).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1704822     DOI: 10.1093/carcin/12.2.285

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

Authors:  Matthew H Kulke; Jason L Hornick; Christine Frauenhoffer; Susanne Hooshmand; David P Ryan; Peter C Enzinger; Jeffrey A Meyerhardt; Jeffrey W Clark; Keith Stuart; Charles S Fuchs; Mark S Redston
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

2.  Accumulation of O6-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects.

Authors:  S A Kyrtopoulos; V L Souliotis; C Valavanis; V A Boussiotis; G A Pangalis
Journal:  Environ Health Perspect       Date:  1993-03       Impact factor: 9.031

Review 3.  Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research.

Authors:  G N Wogan
Journal:  Environ Health Perspect       Date:  1992-11       Impact factor: 9.031

4.  Development of a 32P-postlabeling assay for 7-methylguanines in human DNA.

Authors:  R Mustonen; A Försti; P Hietanen; K Hemminki
Journal:  Environ Health Perspect       Date:  1993-03       Impact factor: 9.031

5.  Repair of O6-alkylguanines in the nuclear DNA of human lymphocytes and leukaemic cells: analysis at the single-cell level.

Authors:  J Thomale; F Seiler; M R Müller; S Seeber; M F Rajewsky
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

6.  A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.

Authors:  O A Khan; M Ranson; M Michael; I Olver; N C Levitt; P Mortimer; A J Watson; G P Margison; R Midgley; M R Middleton
Journal:  Br J Cancer       Date:  2008-05-13       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.